The Antiinflammatory Action and Pharmacokinetics of a Novel Glucosamine-based Di-Peptide Aminosugar by Gilzad-Kohan, Mohammad H. et al.
Chapman University
Chapman University Digital Commons
Pharmacy Faculty Articles and Research School of Pharmacy
2013
The Antiinflammatory Action and
Pharmacokinetics of a Novel Glucosamine-based
Di-Peptide Aminosugar
Mohammad H. Gilzad-Kohan
University of Alberta
Kamaljit Kaur
Chapman University, kkaur@chapman.edu
Fakhreddin Jamali
University of Alberta
Follow this and additional works at: http://digitalcommons.chapman.edu/pharmacy_articles
Part of the Medicinal and Pharmaceutical Chemistry Commons, and the Medicinal Chemistry
and Pharmaceutics Commons
This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.
Recommended Citation
Gilzad-Kohan, Mohammad H., Kamaljit Kaur, and Fakhreddin Jamali. "The Antiinflammatory Action and Pharmacokinetics of a
Novel Glucosamine-based Di-Peptide Aminosugar." Journal of Pharmacy & Pharmaceutical Sciences 16.2 (2013): 279-288.
The Antiinflammatory Action and Pharmacokinetics of a Novel
Glucosamine-based Di-Peptide Aminosugar
Comments
This article was originally published in Journal of Pharmacy and Pharmaceutical Sciences, volume 16, issue 2, in
2013.
Copyright
University of Alberta
This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/pharmacy_articles/29
J Pharm Pharm Sci (www.cspsCanada.org) 16(2) 279 - 288, 2013 
 
  
 
 
279 
The Antiinflammatory Action and Pharmacokinetics of a Novel 
Glucosamine-based Di-Peptide Aminosugar 
 
Mohammad H. Gilzad-Kohan, Kamaljit Kaur and Fakhreddin Jamali 
 
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada 
 
Received, April 19, 2013; Revised, June 14, 2013; Accepted, June 17, 2013; Published, June 20, 2013. 
 
ABSTRACT – Purpose. We have previously shown favorable in vitro gut permeability for three novel di-
peptide esters of glucosamine (GlcN) likely facilitated by the peptide transporter 1 (PepT1). Herein, we report 
the development of a novel assay for the determination of bioavailability of the peptide ester of interest, the 
anti-inflammatory properties of a glycine-valine ester derivative of GlcN (GVG) as well as its pharmacokinetics 
under healthy and inflammatory conditions. Methods. A pre-column derivatization (with 9-
fluorenylmethoxycarbonyl) HPLC assay was developed to study bioavailability of GVG, GlcN or cleaved GlcN 
in the rats that were cannulated in their right jugular vein for blood collection.  The compounds of interest were 
orally administered to both healthy and arthritic rats. Serial blood samples and urine were collected and assayed 
for the compounds. The stability of the GVG was also tested after incubation with the rat feces. Efficacy of 
GVG was tested in inflamed rats (injection of 0.2 mL of Mycobacterium butyricum in squalene) following GVG 
(20 and 30 mg/kg/day GlcN equivalent) or GlcN (20 and 90 mg/kg/day) administration. Arthritis index was 
calculated at the end of the experiment. Results. The assay was linear (ranged between 0.05-20 μg/mL) and 
reproducible (intra- and inter-day<10%).  Among the tested compounds, only GVG showed a significantly 
higher plasma concentrations and urinary excretion than GlcN (≈3-fold increase).  GVG showed a favorable 
stability in the rat feces. Adjuvant arthritis was completely prevented with doses greater than 20 mg/kg/day with 
GVG being 3-fold more potent than GlcN. Conclusion. The examined glycine-valine-GlcN di-peptide 
aminosugar is a potent anti-inflammatory compound due to its favorable properties to deliver GlcN into the 
systemic circulation. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
___________________________________________________________________________________ 
 
INTRODUCTION 
 
Glucosamine (GlcN) is a naturally occurring 
amino-sugar with anti-inflammatory properties (1-
3). However, the oral bioavailability of GlcN is 
limited and, since, at least outside Europe, it is not a 
regulated compound, the quality of the marketed 
products and also those used in clinical trials are 
questionable (4). The latter issues have been 
suggested to be, at least in part, behind the 
controversy in the effectiveness of GlcN. 
Nevertheless, GlcN is vastly used in the treatment 
of osteoarthritis (OA) (5). 
One approach for improving the oral bioavailability 
of poorly absorbed polar drug such as GlcN is to 
synthesize prodrugs that facilitate their 
translocation across the intestinal wall by the di/tri-
peptide oligopeptide transporter (PepT1). Recently, 
we have designed and synthesized several mono- 
and di-peptide GlcN ester and amide derivatives 
(6). Among the tested prodrugs, an ester derivative, 
Gly-Val-COO-GlcN (GVG) showed increased in 
vitro permeability through everted rat gut, which 
was, at least in part, efficiently mediated by PepT1. 
GVG was relatively stable in the gut, readily 
crossed the gut wall in vitro and was rapidly 
hydrolyzed to yield the parent drug (GlcN) after 
incubation with liver homogenates; therefore, it 
appeared to be a promising candidate for further 
investigation. 
The first aim of this study was to investigate 
the in vivo bioavailability of three di-peptide esters 
of GlcN, GVG, phenylalanine-phenylalanine-COO-
GlcN (FFG), and valine-glycine-COO-GlcN 
_________________________________________ 
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(VGG), relative to GlcN. For this purpose, we 
developed a sensitive HPLC assay for simultaneous 
measurement of GlcN and its ester derivative, 
GVG, based on fluorescence detection. Both GlcN 
and GVG lack chromophores; hence, they were 
derivatized with 9-fluorenylmethoxycarbonyl 
(Fmoc), a highly fluorescent compound (7,8).  
The second aim of this study was to assess 
GVG stability in the rat feces. It has been 
previously shown that GlcN can be degraded by 
feces, which in turn, causes reduced bioavailability 
(9). 
The third aim of this study was to explore the 
efficacy of GVG in prevention of experimental 
inflammation in a rat model of adjuvant arthritis 
(AA), which has been used for decades to test 
antirhematoid drugs (10). There are several studies 
indicating that GlcN at high doses, which is 
associated with high plasma concentrations, is 
effective in prevention and controlling 
inflammatory conditions including AA (1,2). We, 
hence, hypothesized that a GlcN prodrug (e.g. 
GVG) with a relatively high bioavailability is a 
novel drug suitable for the treatment of 
inflammatory conditions such as AA. The new 
GlcN derivative can produce therapeutic GlcN 
levels with smaller daily doses compared to GlcN. 
This is expected to improve patient’s compliance as 
the available product are excessively large; a 
typical 500 mg tablet of GlcN weighs 1.4 g. 
Finally, we investigate the possible effect of 
inflammation on the pharmacokinetic of GVG. 
Inflammation is known to cause alteration on the 
expression of several transporters (11). It has been 
reported that Dextran sulfate sodium-induced rat 
colitis does not alter PepT1 substrate bioavailability 
despite certain modifications in the mRNA 
expression (12). 
 
MATERIALS AND METHODS 
 
Chemicals 
The examined dipeptides (GVG, FFG and VGG) 
were synthesized in our lab based on a previously 
described method (6). D-(+)-GlcN, 9-
fluorenylmethoxycarbonyl chloride (Fmoc-Cl), 
mannosamine HCl, 1-aminoadmantane HCl 
(amantadine), boric acid, sodium hydroxide, lactic 
dehydrogenase, aspergillus nitrate reductase , FAD, 
NADPH, tris base, tris hydrochloride, sodium 
nitrite, sodium nitrate, pyruvic acid, phosphoric 
acid, naphthalene ethylene diamine, and 
sulphanilamide were purchased from Sigma- 
Aldrich (St. Louis, MO, USA). Mycobacterium 
butyricum was purchased from Difco (Detroit, MI, 
USA).  Squalene was purchased from Kodak 
(Rochester, NY, USA). HPLC grade acetonitrile 
and water were purchased from Caledon 
Laboratories Ltd, (ON, Canada). All other 
chemicals and solvents were commercial products 
of analytical or HPLC grades. 
 
Animals 
The experimental protocol was approved by the 
University of Alberta Animal Care Committee. 
Male Sprague–Dawley rats (250–280 g) were 
acclimatized in a temperature-controlled room with 
a 12:12 h dark/light cycle and fed with standard 
rodent chow food containing crude protein 23%, 
crude fat 4.5%, crude fiber 6%, ash 8%, and 
mineral 2.5%. 
 
Simultaneous HPLC assay for GlcN and GVG 
Plasma concentration and/or urinary excretion of 
GlcN was determined and used as a measure of 
bioavailability for all tested compounds. In 
addition, for GVG only, the intact pro-drug was 
measured to test its presence in various biological 
samples. The HPLC system consisted of a 
Shimadzu Prominence HPLC system (Mandel 
Scientific, Guelph, ON Canada) equipped with a 
RF-10AxL fluorescence detector, a LC-20AT 
pump, a DGU-20A5 degasser, a SIL-20A auto-
sampler, a CTO-20AC column oven, a CBM-20A 
communication bus module and a Phenomenex C18 
(100 mm x 4.6 mm, id 3 µm) reversed phase 
column guarded with a security guard cartridge C18 
(4 mm x3 mm) column. The gradient mobile phase 
consisted of 0.1% acetic acid in HPLC-grade water 
(A) and acetonitrile (B) which was run at 1 
mL/min; the gradient system commenced and 
continued for 17 min with 24% B followed by an 
increase of B to 90% in 1 min. The composition 
was maintained for 10 min and decreased back to 
24% B in 1 min. Column oven temperature was set 
at 37º C. The detection was carried out at excitation 
and emission wavelength of 256 nm and 315 nm, 
respectively. The sample run time was 38 min. The 
peak height was used for all calculations. 
Adequate amount of GlcN.HCl or GVG.HCl 
was dissolved in 10 mL water to yield a 1 mg/mL 
(based on free base) stock solution of each 
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compound. The stock solutions were further diluted 
with water to give standard solutions containing 
0.1, 1, 10, 20 and 40 μg/mL. Aliquots of 0.1 mL 
plasma were spiked with the standard solutions to 
yield the calibration solutions containing 0.05, 0.5, 
5, 10 and 20 μg/mL of each compound. The 
standard curves were constructed by plotting 
GlcN:IS or GVG:IS peak height ratio versus the 
added concentration of GlcN or GVG. A 30 μg/mL 
mannosamine HCl (IS) solution was used as the 
internal standard (IS). Fmoc-chloride was used as 
the derivatizing reagent at a concentration of 8 mM 
in acetonitrile. Borate buffer (0.2 M) was prepared 
by dissolving 6.18 g boric acid in 425 mL water 
followed by pH adjustment to 8.5 using NaOH (10 
M). A 300 mM solution of amantadine was 
prepared in acetonitrile/water (1:1, v/v) and was 
used as a scavenger for the unreacted Fmoc-
chloride. 
To 0.1 mL of rat plasma was added 50 μL of IS 
and proteins precipitated with 200 μL of cold 
acetonitrile followed by 1 min vortex-mixing and 
centrifugation for 3 min at 10,000 g. 100 μL of the 
supernatants were transferred into clean test tubes 
and 50 μL of each borate buffer and a freshly 
prepared Fmoc-chloride solution were added. After 
1 min vortex-mixing the samples were incubated in 
a water bath at 30º C for 30 min. Subsequently, 50 
μL of amantadine was added and samples were 
diluted with 1 mL acetonitrile/water (1:1) followed 
by injection of aliquots (5 μL) into HPLC. 
Three calibration curves were prepared on the 
same day to determine intra-day variability. The 
experiment was repeated on three different days to 
determine the inter-day variability. The accuracy 
was determined from % error = (mean observed 
concentration – added concentration) x100/ added 
concentration. The coefficient of variation (CV%) 
was used to estimate the assay precision. 
The percent recovery of GlcN, GVG, and IS 
from plasma was estimated from % recovery = 
(compound peak height in plasma sample / 
compound peak height in water sample) x 100.  
In order to determine the short term stability, 
samples (0.05, 0.5, 5 and 20 μg/mL) were 
derivatized and analyzed at 0, 4, 8 and 24 h post-
derivatization. In order to measure the freeze and 
thaw stability, samples were prepared and kept in 
the freezer at -20º C for 24 h. The samples were 
removed from the freezer and allowed to thaw at 
room temperature followed by refreezing for 
another 24 h. Aliquots of the samples were 
derivatized and analyzed after each freeze-thaw 
cycle. At the end of the stability experiments, the % 
accuracy and CV% were calculated. 
 
Bioavailability of ester derivatives 
Under oxygen/methoxyflurane anaesthesia, animals 
were cannulated in their right jugular vein as 
previously described (1). Briefly, a polyethylene 
cannula (Dow Corning Corp., Midland, MI, USA) 
tipped with 2 cm of silastic tubing (Becton 
Dickinson, Sparks, MD, USA) was inserted into 
their right jugular vein. Rats were allowed to 
recover overnight. Food was withdrawn from the 
animals 12 h before dosing. They were randomly 
assigned into four different groups (n=8-11/group) 
and received either GlcN, or one of its ester 
prodrugs (GVG, FFG, or VGG) at the equivalent to 
100 mg/kg of GlcN and serial blood samples were 
collected just before administration and at 0.25, 0.5, 
0.75, 1, 1.5, 2, 3, and 4 h post-dose. Samples were 
collected into heparinized tubes and plasma 
separated immediately by centrifugation. Total 
urine output was also collected over a period of 24 
h. All samples were stored at -20º C until analyzed.  
 
Fecal stability of GVG 
Fecal pellets were collected from healthy rats (one 
pellet from each rat; n = 6) and placed in 50 mL 
centrifuge tube, soften by addition of 25 mL 
deionised water, vortex-mixed for 10 min and 
centrifuged at 2500 rpm for 8 min. The fecal 
suspension (1 mL) was transferred into a 1.5 mL 
microcentrifuge tube and centrifuged at 8,300 g for 
5 min. The supernatant was immediately spiked 
with GVG (1.25 mg per each sample). The first set 
of samples was incubated at 37º C for 2 h to assess 
the effect of aerobic intestinal micro-flora. Air was 
removed from the tubes of the second set of 
samples (n=6) by blowing nitrogen (N2) into the 
test tubes.  Thereafter, samples were incubated at 
37º C for 2 h to assess the effect of anaerobic 
intestinal micro-flora. The third set of samples was 
placed in a 4º C refrigerator for 2 h in order to study 
the effect of the feces compositions on GVG 
stability. A GVG solution (1.25 mg) with addition 
of no feces was set separately as a negative control. 
Control sample was incubated for 2 h at 37º C. At 
the end of the experiment the amount of GVG was 
determined using HPLC.  
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Effect of inflammation on GVG bioavailability 
Animals were randomly divided into two groups: 
Inflamed or healthy control (n = 6). Adjuvant 
arthritis was induced in the inflamed animals by 
injecting 0.2 mL of Mycobacterium butyricum in 
squalene (50 mg/mL) in the tail base. Healthy rats 
were injected 0.2 mL of saline. On day 14, when 
the sign and symptoms of arthritis appear in the 
inflamed group (1), all animals were cannulated in 
their right jugular vein. After an overnight recovery 
period, a dose of GVG (equivalent to 100 mg/kg of 
GlcN base) was administered and serial blood 
samples were collected before dosing and at 0.25, 
0.5, 0.75, 1, 1.5, 2, 3, and 4 h post dosing. The total 
0-24 h urine output was also collected for the 
determination of GVG and GlcN. 
 
GVG efficacy in prevention of adjuvant arthritis 
Rats were randomly assigned into 6 groups (n=6 
/group): Control-Healthy, Control-Inflamed, GlcN-
20, GVG-20, GVG-30, and GlcN-90. On day one, 
all inflamed rats were injected 0.2 mL of 
Mycobacterium butyricum in squalene (50 mg/mL). 
Control-Healthy animals were injected 0.2 mL of 
normal saline.  GlcN or GVG administration was 
commenced on the first day of experiment as a 
preventive measure. In this study we chose 2 daily 
GlcN equivalent dosage regimens: First, 30 mg/kg 
GVG vs 90 mg/kg GlcN to confirm efficacy at 
doses higher the minimum effective GlcN dose (40 
mg/kg, (13)), and second, 20 mg/kg GVG versus 20 
mg GlcN, a regimen below the minimum effective 
GlcN dose. 
During the experiment, body weight gain and 
paw thickness (using a caliper with a sensitivity of 
25 µm, Mitutoyo Canada Inc., Toronto, ON) were 
measured daily. On the last day of experiment, 
serum nitrite was measured using a previously 
described method (14). Nitrite standard curves were 
linear over the concentration range of 3 - 200 µM 
(r2 ≥ 0.99, coefficient of variation ≤10%). 
On day 18 after injection of the adjuvant, 
arthritis index was calculated according to a 
previously described method (15). A maximum 
score of 14 could be assigned to each animal as 
followed: On a 0–4 basis hind paws were scored 
where zero was no virtual sign of arthritis, one was 
involvement of a single joint, two was involvement 
of more than one joint and/or ankle, three was 
involvement of several joints and ankle with 
moderate swelling, and four was involvement of 
several joints and ankle with severe swelling. Each 
forepaw was scored on a 0–3 basis scoring system 
where 0 was involvement of none of the joints, one 
was involvement of single joint, two was 
involvement of more than one joint and/or wrist, 
and three was involvement of wrist and joints with 
moderate-to-severe swelling. 
 
Data treatment and statistical analysis 
The non-compartmental approach was used to 
calculate pharmacokinetic parameters. The area 
under the plasma concentration-time curve (AUC) 
0-4 h post-dose was calculated using the trapezoidal 
method. The peak concentration (Cmax) and the time 
of its attainment (tmax) were the experimentally 
observed values. The percent urinary excretion was 
estimated from (total excreted in urine in 24 h/dose) 
X 100.  
Data are presented as mean ± SD. Differences 
between two means were assessed using the 
Student’s t-test (Table 2). For more than two 
means, we used the one-way ANOVA followed by 
Bonferroni post-test. All statistical analyses were 
carried out using Prism software (GraphPad 
Software Inc., San Diego, CA, USA) at p < 0.05. 
 
 
RESULTS 
 
Simultaneous HPLC assay for GlcN and GVG 
The HPLC peaks for Fmoc derivatized GlcN and 
mannosamine (IS) appeared as pairs of anomers as 
has been previously reported (8). The anomers 
resolved at 11.6 and 14.1 min for the IS and 12.7 
and 15.5 min for GlcN (Figure 1). The second peak 
of each compound was used in order to quantify the 
samples. GVG resolved as a single peak at a 
retention time of 17.7 min. No interfering peak was 
observed in the blank rat plasma or urine samples. 
The assay was linear over the range of 0.05-20 
μg/mL for both GVG and GlcN in rat plasma 
(r2≥0.99). The lowest limit of quantification was set 
at 50 ng/mL for both compounds. The peak height 
measurement approach provided lower variability 
in response than that of the peak area, hence, the 
former was used throughout. The inter- and intra-
day variations were less than 10% for all 
concentrations and the accuracy ranged from -1.4 to 
2.4% for GlcN and -6 to 8% for GVG. 
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Figure 1. HPLC chromatograms of (a) blank rat plasma, (b) rat plasma at t=4 h post-dosing (GVG 100 mg/kg); only GlcN 
peaks appears in plasma after GVG administration, and (c) blank rat plasma spiked with 1 µg/mL GlcN and GVG. Keys: 
M, mannosamine (IS); G, GlcN; GVG, Gly-Val-COO-GlcN 
 
 
The percent recovery of the IS from rat plasma was 
96.1±3. The % recovery of GVG was 99±5.3, 
98.2±5.1, 97±3.7, 95.9±9.2, and 94.2±7.3 for the 
0.05, 0.5, 5, 10, and 20 μg/mL samples in rat 
plasma, respectively.  Percent recovery of GlcN 
from rat plasma appeared to be 105±6.1, 97.8±7, 
103.2± 4.3, 103.3±2.2, and 99.8±6.2% from the 
0.05, 0.5, 5, 10, and 20 μg/mL samples, 
respectively. 
Derivatized GVG and GlcN were stable in all 
plasma samples during the analysis process and 24 
h after derivatization; stability was > 91 % for all 
samples.  GVG and GlcN were also appeared to be 
stable in rat plasma after three freeze and thaw 
cycles. 
 
Bioavailability of GlcN versus its ester 
derivatives 
Figure 2 depicts the mean plasma concentration of 
GlcN after administration of equivalent doses (100 
mg/kg of GlcN base) of GlcN or its ester 
derivatives. All compounds were rapidly absorbed 
(tmax ≤ 0.5 h). However, among all tested 
compounds, only GVG showed a significantly 
higher oral bioavailability as compared to GlcN 
(Table 1). FFG and VGG only showed an 
insignificant trend toward increased bioavailability 
as compared to GlcN. GVG also exhibited a 
significant increase in percent of dose excreted in 
the urine as compared to the other tested 
compounds.   No   significant    differences    were  
 
 
Figure 2. Mean GlcN plasma concentration (±SD) 
versus time profile following oral administration of 
GlcN or the ester derivatives of GlcN to rats (n=8-
11/group). All doses were equivalent to100 mg/kg of 
GlcN base.  
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Table 1. Bioavailability parameters of GlcN and its ester derivatives 
Compound GlcN VGG FFG GVG 
Cmax (µg/mL) 3.7±0.6a 4.4 ± 1.4a 4.7 ± 1.6a 14.6 ± 4.9b 
     
AUC0-4 (µg.h/mL) 6.6±1.2c 7.8 ± 1.6c 8.1 ± 1.5c 19.2 ± 3.7d 
     
% of dose excreted in 
the urine0-24 
2.2±0.3e 2.6 ± 0.5e 2.8 ± 0.7e 6.8 ± 0.6f 
For all compounds, a single oral dose equivalent to 100 mg/kg of GlcN base was orally administered to the animals (n=8-
10/group). Data are shown as mean± SD. Different superscript characters indicate significant differences between means in 
a row (p < 0.05). 
 
noticed among GlcN, FFG, and VGG in any of the 
calculated pharmacokinetic parameters. 
No intact GVG was detected in plasma or urine 
after its oral administration. 
 
Fecal stability of GVG 
Figure 3 depicts the percent remaining of GVG 
after 2 h incubation under control (no feces), 
aerobic, and anaerobic conditions at 37 and 4º C. 
Incubation of GVG with rat faces resulted in almost 
33% loss in all samples. There were no significant 
differences between the amounts of GVG that 
remained at the end of the experiment under 
aerobic, anaerobic, or 4º C conditions. At the end 
of the experiment, approximately 97% of GVG 
remained intact in the control samples. 
 
 
Figure 3. The average percent GVG remaining after 2 h 
incubation at 37º C (control, aerobic and anaerobic) or at 
4º C. Error bars represent standard deviation. The same 
character indicates no significant difference between 
means at p < 0.05; n=6/group. 
 
Effect of inflammation on GVG bioavailability 
Inflammation did not significantly alter the oral 
bioavailability of a single oral dose of GVG (100 
mg/kg of GlcN base) as no significant differences 
were noticed between the groups in Cmax, AUC0–4 
and the percent of dose excreted in the urine in 24 h 
(Figure 4 and Table 2).  
 
 
Figure 4. Mean (n=6/group) plasma concentration 
(±SD) versus time profiles of glucosamine in control and 
inflamed rats following oral administration of a single 
dose equivalent to 100 mg/kg GlcN base. 
 
GVG efficacy in prevention of adjuvant arthritis 
Adjuvant arthritis emerged in the rats (Control-
Inflamed) that received Mycobacterium butyricum 
but were not treated with either GlcN or GVG. 
They exhibited significant increase in paw 
thickness (Figure 5) as compared to the Control-
Healthy animals and, at the end of the experiment 
(day 18) had arthritis index of 9.1 ± 0.8. No sign of 
arthritis was observed in Control-Healthy group as 
well as in the rats that were treated with 90 
mg/kg/day GlcN (GlcN-90) or 20 and 30 
mg/kg/day GVG. Administration of 20 mg/kg/day 
GlcN (GlcN-20) did not prevent adjuvant arthritis 
but the severity of the disease was significantly less 
than those observed for Control-Inflamed (arthritis 
index, 4.1 ± 1.1). 
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Table 2. Bioavailability parameters of GVG in control and inflamed rats (n=6/group) 
Group Inflamed Control 
Cmax (µg/mL) 14.01 ± 1.7 14.25 ± 0.6 
   
AUC0-4 (µg.h/mL) 19.1 ± 1.1 18.97 ± 0.5 
   
% of dose excreted in the urine0-24 7.1 ± 0.6 6.9 ± 0.5 
 
 
 
 
Figure 5. Average increase in paw thickness at the 
end of the experiment. Error bars represent standard 
deviation. The same character indicates no significant 
difference between means at p < 0.05; n = 6/group.  
 
 
The effect of the treat ments on the weight gain 
(Figure 6) and serum nitrite levels (Figure 7) were 
similar to those observed for adjuvant arthritis.  
 
 
 
 
 
Figure 6. The average percent weight gain (+SD) from 
baseline. Error bars represent standard deviation. The 
same character indicates no significant difference 
between means at p < 0.05; n = 6/group. 
 
Figure 7. The effect of inflammation and prevention 
with GlcN or GVG on serum nitrite concentration in 
inflamed rats (n = 6/group); error bars represent standard 
deviation. The same character indicates no significant 
difference between means at p < 0.05. 
 
DISCUSSION 
 
Assay of GVG and GlcN 
We developed a sensitive HPLC assay for 
simultaneous measurement of GlcN and its ester 
derivative, GVG, based on fluorescence detection. 
As neither GlcN nor GVG contain fluorophore 
groups, we derivatized them to Fmoc-GlcN and –
Fmoc-GVG. Fmoc-Cl has been used since 1980s 
for HPLC analysis of amino acids (7). It rapidly 
and almost completely reacts with primary and 
secondary amines under alkaline conditions. The 
solvent gradient program and the addition of 0.1% 
acetic acid to the mobile phase resulted in sharp 
and resolved peaks (Figure 1). Most of the plasma 
interfering peaks eluted before the appearance of 
the peaks of interest. The derivatization method 
yields two equal sized but completely resolved 
anomers (stereoisomers of cyclic sugars that differ 
in their configuration at the anomeric carbon) peaks 
(8). The excessive amount of the derivatizing agent 
was removed by adding amantadine to form a 
hydrophobic complex that eluted at the end of the 
run time and before the next injection. To prevent 
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pump pressure build-up, the injection volume was 
set at 5 μL. 
The method was linear over the examined 
range with suitable sensitivity and acceptable 
accuracy and reproducibility.  
 
Bioavailability 
All of the three examined di-peptide GlcN esters 
demonstrated trends toward a greater oral 
bioavailability than the parent compound but the 
change reached statistical significance only for 
GVG. This is in agreement with the previously 
reported seven-fold greater than GlcN permeability 
across the everted rat gut for GVG (6). The 
enhanced permeability was attributed to the 
involvement of PepT1 since incubation in the 
presence of PepT1 inhibitor (Gly-Sar) reduced the 
process to the level of that observed for GlcN (6). 
Our observation may be proven useful in predicting 
oral absorption of these compounds following 
administration to humans, since rats appear to be 
suitable predictors of drug absorption by humans 
(16). The high permeability of GVG is due, likely, 
to the recognition of the conjugate by the PepT1, as 
a specific PepT1 substrate; Gly-Sar completely 
inhibited transport of GVG (6). In general, the 3-
dimensional conformation properties of a substrate 
govern whether a substrate has affinity for PepT1 
(17-19). GVG seemed to have the appropriate 
stereochemical and conformational features. There 
are several other examples in which researchers 
have attempted to improve oral absorption of 
various poorly absorbed drugs via attachment to 
amino acids or dipeptides in order to resemble 
PepT1 substrates, mostly through ester bonds (20-
23).  Similar to GVG, the glycine-valine ester 
prodrug of acyclovir appeared to be more 
efficiently absorbed across the intestinal mucosa as 
compared to other ester derivatives (20). 
GVG has been shown to be relatively stable in 
the gut; it readily crosses the gut wall and rapidly 
yields the parent drug upon incubation with liver 
homogenates (6). Although it has been shown that 
GVG remains intact during movement from 
mucosal toward serosal side in the rat small 
intestine (6), we were not able to detect any intact 
GVG in the systemic circulation. In other words 
GVG seems to be transported into the portal vein 
and then cleaved into GlcN and the di-peptide 
moiety either in the liver. 
In general, the activation of the prodrug such as 
GVG after its in vivo hydrolysis , is not expected to 
raise toxicity concerns since the activation 
byproducts are a dipeptide and/or amino acids and 
the parent drug (20,24). 
The low bioavailability of GlcN is attributed to, 
at least, two mechanisms, the inefficiency of the 
involved transporters (i.e., GLUT-2) and the loss 
due to the uptake by the gut microflora (9). It has 
been shown that incubation of 1.25 mg GlcN with 
the rat feces results in 95% loss.  For GVG only 
33% loss was detected over a 2 h incubation period 
(Figure 3). The mechanism of this loss is unclear as 
it occurs under various conditions (aerobic, 
anaerobic and/or 4º C) that may put the mere 
involvement of microflora into question. 
Nevertheless, the observed fecal stability of GVG 
as compared with GlcN may contribute to the 
greater bioavailability of the latter. 
 
Efficacy 
The rat model of AA mimics human rheumatoid 
arthritis which has been vastly used for decades to 
assess the efficacy of antirheumatic agents (10). 
We used this model to compare the anti-
inflammatory effects of GVG with GlcN. 
Assuming a three-fold greater bioavailability of 
GVG as compared with GlcN, we first compared 
30 mg/kg/day of the former with 90 mg/kg/day 
(GlcN equivalent) of the latter to assess the efficacy 
of the same GlcN exposure following 
administration of the two different compounds. We 
noticed that the treatments were equally effective in 
preventing adjuvant arthritis (Figure 5), reduced 
body weight gain (Figure 6) and increased serum 
nitrite level (Figure 7). Considering the fact that the 
oral administration of GVG yields only GlcN in the 
systemic circulation, one can suggest that the 
greater potency of GVG is due to the corresponding 
higher GlcN bioavailability after administration of 
the prodrug as compared to the parent compound. 
To further confirm the observation, we compared 
the two compounds following daily treatment with 
20 mg/kg/day (GlcN equivalent), which was known 
to be below the GlcN effective dose range (13). 
The GVG and not GlcN regimen was effective in 
completely preventing the experimental arthritis.  
This further confirms that, at the dosage level that 
GlcN is not fully effective, GVG prevents the 
emergence of adjuvant arthritis.  
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Effect of inflammation of GVG 
pharmacokinetics 
Inflammation may alter clearance of drugs that are 
efficiently metabolized drugs (25) and also 
influence the expression of some transporters (11). 
Inflammation did not result in such an effect on 
GVG since the plasma GlcN concentration-time 
curves following GVG administration under 
healthy and inflammatory conditions were almost 
superimposable (Figure 4).  This suggest a lack of 
effect of inflammation on the activation of the 
prodrug and/or clearance of the active compound 
(glucosamine) as has been reported earlier (1). 
Similarly, according to Radeva et al (2007), 
experimentally-induced rat colitis, another 
inflammatory condition, does not alter the 
bioavailability of cephalexin or valacyclovir, two 
known PepT1 substrates despite certain 
modifications in the transporter mRNA expression 
(12).  
 
CONCLUSION 
 
A novel dipeptide ester of GlcN, GVG, is found to 
have an increased bioavailability assessed using a 
novel HPLC method. GVG exhibited increased 
anti-inflammatory property through a greater GlcN 
delivery into the systemic circulation. The 
pharmacokinetics of GlcN delivered through GVG 
is not influenced by adjuvant arthritis. If the present 
nonclinical data are extrapolated to humans, GVG 
can be considered as an alternative to other 
antiinflammatory agent that have gastrointestinal 
(26), renal (27) and/or cardiovascular (28) side 
effects.    
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